ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

LeMaitre’s (NASDAQ:LMAT) Q1: Beats On Revenue, Guides for Strong Full-Year Sales

LMAT Cover Image

Medical device company LeMaitre Vascular (NASDAQ: LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12% year on year to $59.87 million. Guidance for next quarter’s revenue was optimistic at $62.5 million at the midpoint, 2.2% above analysts’ estimates. Its GAAP profit of $0.48 per share was 4.6% below analysts’ consensus estimates.

Is now the time to buy LeMaitre? Find out by accessing our full research report, it’s free.

LeMaitre (LMAT) Q1 CY2025 Highlights:

  • Revenue: $59.87 million vs analyst estimates of $57.75 million (12% year-on-year growth, 3.7% beat)
  • EPS (GAAP): $0.48 vs analyst expectations of $0.50 (4.6% miss)
  • Adjusted EBITDA: $15.18 million vs analyst estimates of $15.57 million (25.4% margin, 2.5% miss)
  • The company lifted its revenue guidance for the full year to $245.5 million at the midpoint from $239.1 million, a 2.7% increase
  • EPS (GAAP) guidance for the full year is $2.16 at the midpoint, missing analyst estimates by 3.5%
  • Operating Margin: 21.1%, down from 22.2% in the same quarter last year
  • Organic Revenue rose 13% year on year (11% in the same quarter last year)
  • Market Capitalization: $2.05 billion

Chairman/CEO George LeMaitre said, “Q1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.”

Company Overview

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

Sales Growth

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, LeMaitre’s 13.7% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers.

LeMaitre Quarterly Revenue

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. LeMaitre’s annualized revenue growth of 15.6% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. LeMaitre Year-On-Year Revenue Growth

We can dig further into the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, LeMaitre’s organic revenue averaged 14.5% year-on-year growth. Because this number aligns with its normal revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results. LeMaitre Organic Revenue Growth

This quarter, LeMaitre reported year-on-year revenue growth of 12%, and its $59.87 million of revenue exceeded Wall Street’s estimates by 3.7%. Company management is currently guiding for a 11.9% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 8.9% over the next 12 months, a deceleration versus the last two years. Still, this projection is commendable and suggests the market is forecasting success for its products and services.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories.

Operating Margin

LeMaitre has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 21.3%.

Analyzing the trend in its profitability, LeMaitre’s operating margin of 23.4% for the trailing 12 months may be around the same as five years ago, but it has increased by 7.6 percentage points over the last two years.

LeMaitre Trailing 12-Month Operating Margin (GAAP)

This quarter, LeMaitre generated an operating profit margin of 21.1%, down 1.1 percentage points year on year. This reduction is quite minuscule and indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

LeMaitre’s EPS grew at an astounding 18.1% compounded annual growth rate over the last five years, higher than its 13.7% annualized revenue growth. However, we take this with a grain of salt because its operating margin didn’t expand and it didn’t repurchase its shares, meaning the delta came from reduced interest expenses or taxes.

LeMaitre Trailing 12-Month EPS (GAAP)

In Q1, LeMaitre reported EPS at $0.48, up from $0.44 in the same quarter last year. Despite growing year on year, this print missed analysts’ estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects LeMaitre’s full-year EPS of $1.98 to grow 17.3%.

Key Takeaways from LeMaitre’s Q1 Results

It was great to see LeMaitre’s full-year revenue guidance top analysts’ expectations. We were also glad its organic revenue outperformed Wall Street’s estimates. On the other hand, its full-year EPS guidance missed significantly and its EPS guidance for next quarter fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 1.1% to $89.25 immediately following the results.

So do we think LeMaitre is an attractive buy at the current price? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.